Prediction of tuberculosis treatment outcomes using biochemical makers with machine learning.

Prediction of tuberculosis treatment outcomes using biochemical makers with machine learning.

Publication date: Feb 17, 2025

Tuberculosis (TB) continues to pose a significant threat to global public health. Enhancing patient prognosis is essential for alleviating the disease burden. This study aims to evaluate TB prognosis by incorporating treatment discontinuation into the assessment framework, expanding beyond mortality and drug resistance. Seven feature selection methods and twelve machine learning algorithms were utilized to analyze admission test data from TB patients, identifying predictive features and building prognostic models. SHapley Additive exPlanations (SHAP) were applied to evaluate feature importance in top-performing models. Analysis of 1,086 TB cases showed that a K-Nearest Neighbor classifier with Mutual Information feature selection achieved an area under the receiver operation curve (AUC) of 0. 87 (95% CI: 0. 83-0. 92). Key predictors of treatment failure included elevated levels of 5′-nucleotidase, uric acid, globulin, creatinine, cystatin C, and aspartate transaminase. SHAP analysis highlighted 5′-nucleotidase, uric acid, and globulin as having the most significant influence on predicting treatment discontinuation. Our model provides valuable insights into TB outcomes based on initial patient tests, potentially guiding prevention and control strategies. Elevated biomarker levels before therapy are associated with increased risk of treatment discontinuation, indicating their potential as early warning indicators.

Open Access PDF

Concepts Keywords
Biomarker Adult
Expanding Aged
Neighbor Algorithms
Tuberculosis Antitubercular Agents
Uric Antitubercular Agents
Biomarkers
Biomarkers
Discontinuation
Female
Humans
Machine Learning
Machine learning
Male
Middle Aged
Prognosis
ROC Curve
Treatment Outcome
Treatment outcomes
Tuberculosis
Tuberculosis
Young Adult

Semantics

Type Source Name
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH treatment failure
drug DRUGBANK Uric Acid
drug DRUGBANK Creatinine
pathway REACTOME Reproduction
disease MESH Infectious Diseases
drug DRUGBANK Guanosine
drug DRUGBANK Coenzyme M
disease MESH Pulmonary Diseases
drug DRUGBANK Bedaquiline
drug DRUGBANK Delamanid
drug DRUGBANK Spinosad
disease MESH infection
disease MESH Adverse drug reactions
disease MESH complications
disease MESH hyperuricemia
disease IDO process
disease MESH HIV infection
pathway REACTOME HIV Infection
drug DRUGBANK Trestolone
drug DRUGBANK Methyl isocyanate
drug DRUGBANK Flunarizine
drug DRUGBANK Saquinavir
disease MESH confusion
disease IDO algorithm
disease MESH thrombocytopenia
disease IDO history
disease MESH Comorbidity
disease MESH respiratory diseases
disease MESH Digestive system diseases
disease MESH Hypertension

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *